|
|
|
|
New service offers hope for thyroid cancer patients
A NEW service pioneered in the North East is giving fresh hope to thyroid cancer patients.The drug levothryoxine is prescribed to prevent the cancer returning after patients have had their thyroid removed. It is also used to...
|
|
|
Today's News: New service offers hope for thyroid cancer patients
A NEW service pioneered in the North East is giving fresh hope to thyroid cancer patients.The drug levothryoxine is prescribed to prevent the cancer returning after patients have had their thyroid removed. It is also used to...
|
|
|
Novo Nordisk says Victoza cleared for EU market
* Diabetes treatment Victoza gets EU marketing approval * Approval was expected after EU drugs agency recommendation * Launch planned for this year and in 2010 * Novo says approval does not change 2009 outlook COPENHAGEN (Reuters) - Danish...
|
|
|
Researchers identify protein destructing tumour suppressor p53
Researchers at The University of Texas, Maryland Anderson Cancer Center have identified a protein that marks the tumour suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.The new protein,...
|
|
|
UPDATE 1-Novo Nordisk says Victoza cleared for EU market
COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's diabetes drug Victoza, a key driver for future sales, has won European Commission approval for marketing across the European Union, the company said on Friday.The...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key drugs appear.Analysts...
|
|
|
Vivacta Raises $4.5 Million
Vivacta announced that following successful development of its TSH (Thyroid Function) test, together with prototype commercial readers it has closed a $4.Vivacta Raises $4.5 Million.
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Boxed warning not to use in cases of severe heart failure * Shares close 1.9 percent lower as European shares fall (Adds FDA...
|
|
|
UPDATE 4-Sanofi wins FDA approval for heart drug Multaq
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly offset a looming sales drop as generics to several key drugs appear.Analysts...
|
|
|
Sanofi wins FDA approval for heart drug
Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see Multaq, put forward as a...
|
|
|
F.D.A. Approves Sanofi Heart Treatment
PARIS (Reuters) The drug maker Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the company partly recoup a future sales drop as generics to several crucial drugs appear.Analysts see...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis ( SNY - news - people ) won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
* U.S.FDA clears Multaq for atrial fibrillation, flutter * Sanofi says plans commercial launch this summer * Multaq not for patients with severe heart failure * Sanofi shares up as much as 1.7 pct, outperform peers (Adds background on...
|
|
|
UPDATE 3-Sanofi wins FDA approval for Multaq heart drug
PARIS, July 2 (Reuters) - Sanofi-Aventis won approval to sell heart treatment Multaq in the United States, a move that should help the French drugmaker partly recoup a future sales drop as generics to several key drugs appear.Analysts see...
|
|
|
Papillary thyroid carcinoma on sonography
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Clinical Imaging, 07/02/09 Print Save in My Library Free Abstract Li QS et al.- CDUS plays an important role in the early detection of PTC and cervical...
|
|
|
Footballer bounces back from cancer
Swan Districts player Dean Ipaviz has battle his way back from cancer.Picture: Dominique Menegaldo BRAVERY is recognised as a key value on the football field, but Swan Districts defender Dean Ipaviz knows a lot about being courageous away...
|
|
|
Prevalence of Autoimmune Thyroiditis in Children with Celiac Disease and Effect of Gluten Withdrawal
_ Prevalence of Autoimmune Thyroiditis in Children with Celiac Disease and Effect of Gluten Withdrawal.
|
|
|
Cancer treatment room not radiation-proof - report
A cancer treatment room is standing idle at Wellington's new hospital after being found to not be radiation-proof.The radioactive iodine room for thyroid cancer treatment is 'not fit for purpose', according to Capital and Coast...
|
|
|
New Hospital Cancer Treatement Room Not Radiation-proof: Report
Voxy News Engine Wellington, July 2 NZPA - A cancer treatment room is standing idle at Wellington's new hospital after being found to not be radiation-proof.The radioactive iodine room for thyroid cancer treatment is 'not fit for...
|
|
|
Cancer centre needs fixing
Health Co Construction faults and space constraints are delaying cancer treatment at Wellington's new $360-million hospital.A specially built radiation treatment room at Wellington Hospital is not radiation proof, and a new $4.9 million...
|
|
|
[Head and Neck Cancer] Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symp
This Article Google Scholar Social Bookmarking Received June 26, 2008 Accepted February 9, 2009 Martin J.Schlumberger,* Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato G. Martins, Laura D. Locati, Barbara Jarzab, Furio Pacini,...
|
|
|
The V Foundation for Cancer Research Names 2009 Grant Recipients
CARY, N.C.-- The V Foundation for Cancer Research, the leading fundraiser organization for cancer research, announced today that they have awarded the 2009 V Designated Grants. These grants were given to exemplary researchers across the...
|
|
|
UPDATE 1-Sanofi has not received any U.S. news yet on Multaq
PARIS, June 30 (Reuters) - Sanofi-Aventis has not received any news yet from the U.S.health regulator on whether it will clear the French drugmaker's heart drug Multaq, touted as a blockbuster, for marketing. If approved by the Food and...
|
